JP2016509050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509050A5 JP2016509050A5 JP2015558580A JP2015558580A JP2016509050A5 JP 2016509050 A5 JP2016509050 A5 JP 2016509050A5 JP 2015558580 A JP2015558580 A JP 2015558580A JP 2015558580 A JP2015558580 A JP 2015558580A JP 2016509050 A5 JP2016509050 A5 JP 2016509050A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pretreatment
- patient
- day
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 229960000390 fludarabine Drugs 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000001400 myeloablative effect Effects 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 9
- XXHKHLYABSAFDW-UHFFFAOYSA-N 5-amino-5-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]pentane-1,3-diol Chemical compound C1=C(Cl)C(C(CC(O)CCO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 XXHKHLYABSAFDW-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- JGCZBUBEWYTICT-UHFFFAOYSA-N 5-amino-5-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]pentane-1,3-diol;hydrochloride Chemical group Cl.C1=C(Cl)C(C(CC(O)CCO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 JGCZBUBEWYTICT-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 238000011127 radiochemotherapy Methods 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- -1 benzyloxy, phenyl Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766830P | 2013-02-20 | 2013-02-20 | |
| US61/766,830 | 2013-02-20 | ||
| PCT/IB2014/059067 WO2014128611A1 (en) | 2013-02-20 | 2014-02-18 | Treatment of graft versus host disease in transplant patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018219258A Division JP6633170B2 (ja) | 2013-02-20 | 2018-11-22 | 移植患者における移植片対宿主病の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509050A JP2016509050A (ja) | 2016-03-24 |
| JP2016509050A5 true JP2016509050A5 (Direct) | 2017-03-23 |
| JP6441822B2 JP6441822B2 (ja) | 2018-12-19 |
Family
ID=50236228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558580A Active JP6441822B2 (ja) | 2013-02-20 | 2014-02-18 | 移植患者における移植片対宿主病の治療 |
| JP2018219258A Active JP6633170B2 (ja) | 2013-02-20 | 2018-11-22 | 移植患者における移植片対宿主病の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018219258A Active JP6633170B2 (ja) | 2013-02-20 | 2018-11-22 | 移植患者における移植片対宿主病の治療 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160000811A1 (Direct) |
| EP (1) | EP2958624B1 (Direct) |
| JP (2) | JP6441822B2 (Direct) |
| KR (1) | KR102165514B1 (Direct) |
| CN (1) | CN105007981B (Direct) |
| AU (1) | AU2014220377B2 (Direct) |
| BR (1) | BR112015019197A2 (Direct) |
| CA (1) | CA2898565C (Direct) |
| CY (1) | CY1124191T1 (Direct) |
| DK (1) | DK2958624T3 (Direct) |
| EA (1) | EA030783B1 (Direct) |
| ES (1) | ES2873181T3 (Direct) |
| HR (1) | HRP20210891T1 (Direct) |
| HU (1) | HUE054330T2 (Direct) |
| LT (1) | LT2958624T (Direct) |
| MX (1) | MX369631B (Direct) |
| PL (1) | PL2958624T3 (Direct) |
| PT (1) | PT2958624T (Direct) |
| RS (1) | RS61933B1 (Direct) |
| SI (1) | SI2958624T1 (Direct) |
| SM (1) | SMT202100334T1 (Direct) |
| TW (1) | TWI648050B (Direct) |
| WO (1) | WO2014128611A1 (Direct) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA039817B1 (ru) * | 2016-03-08 | 2022-03-16 | Прайотера Лимитед | Лечение пациентов, перенесших трансплантацию гематопоэтических стволовых клеток |
| TWI899057B (zh) * | 2018-07-27 | 2025-10-01 | 愛爾蘭商普萊歐塞拉有限公司 | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 |
| CN117177748A (zh) * | 2020-11-04 | 2023-12-05 | 浩康生物系统公司 | 用于异基因造血干细胞移植的方法 |
| AU2021424131A1 (en) | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
| EP4284348A2 (en) | 2021-01-28 | 2023-12-06 | Priothera SAS | Methods of treatment with s1p receptor modulators |
| CA3250985A1 (en) | 2022-02-16 | 2023-08-24 | Priothera Sas | CAR CELL TREATMENT METHODS IN COMBINATION WITH S1P RECEIVER MODULATORS |
| EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998020932A2 (en) * | 1996-11-15 | 1998-05-22 | Baxter International Inc. | Conditioning for allogeneic stem cell transplantation |
| US6383481B1 (en) | 1998-03-30 | 2002-05-07 | Japan Immunoresearch Laboratories Co., Ltd. | Method for transplantation of hemopoietic stem cells |
| JPH11343242A (ja) * | 1998-03-30 | 1999-12-14 | Otsuka Pharmaceut Co Ltd | 造血幹細胞移植用剤 |
| DE60223699T2 (de) * | 2001-09-27 | 2008-10-30 | Kyorin Pharmaceutical Co., Ltd. | Diarylsulfidderivat, dessen additionssalz und immunsuppressivum |
| AU2003264430B2 (en) * | 2002-09-19 | 2009-03-19 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| PL1772145T3 (pl) | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
| WO2006073126A1 (ja) * | 2005-01-06 | 2006-07-13 | Kissei Pharmaceutical Co., Ltd. | 慢性移植片対宿主症におけるドライアイの予防および治療剤 |
| EP2566954B2 (en) | 2010-05-04 | 2022-11-02 | Yeda Research and Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| CN106309416A (zh) | 2010-05-06 | 2017-01-11 | 诺华股份有限公司 | 二芳基硫醚衍生物的给药方案 |
-
2014
- 2014-02-18 MX MX2015010833A patent/MX369631B/es active IP Right Grant
- 2014-02-18 JP JP2015558580A patent/JP6441822B2/ja active Active
- 2014-02-18 EP EP14708330.7A patent/EP2958624B1/en active Active
- 2014-02-18 EA EA201591522A patent/EA030783B1/ru not_active IP Right Cessation
- 2014-02-18 HR HRP20210891TT patent/HRP20210891T1/hr unknown
- 2014-02-18 LT LTEP14708330.7T patent/LT2958624T/lt unknown
- 2014-02-18 RS RS20210626A patent/RS61933B1/sr unknown
- 2014-02-18 CA CA2898565A patent/CA2898565C/en active Active
- 2014-02-18 BR BR112015019197A patent/BR112015019197A2/pt not_active Application Discontinuation
- 2014-02-18 KR KR1020157022190A patent/KR102165514B1/ko active Active
- 2014-02-18 WO PCT/IB2014/059067 patent/WO2014128611A1/en not_active Ceased
- 2014-02-18 AU AU2014220377A patent/AU2014220377B2/en active Active
- 2014-02-18 CN CN201480009413.4A patent/CN105007981B/zh active Active
- 2014-02-18 SI SI201431824T patent/SI2958624T1/sl unknown
- 2014-02-18 PL PL14708330T patent/PL2958624T3/pl unknown
- 2014-02-18 DK DK14708330.7T patent/DK2958624T3/da active
- 2014-02-18 PT PT147083307T patent/PT2958624T/pt unknown
- 2014-02-18 US US14/768,744 patent/US20160000811A1/en not_active Abandoned
- 2014-02-18 ES ES14708330T patent/ES2873181T3/es active Active
- 2014-02-18 HU HUE14708330A patent/HUE054330T2/hu unknown
- 2014-02-18 SM SM20210334T patent/SMT202100334T1/it unknown
- 2014-02-19 TW TW103105523A patent/TWI648050B/zh active
-
2018
- 2018-01-29 US US15/882,392 patent/US11224604B2/en active Active
- 2018-11-22 JP JP2018219258A patent/JP6633170B2/ja active Active
-
2021
- 2021-06-01 CY CY20211100473T patent/CY1124191T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509050A5 (Direct) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| NZ749192A (en) | Ar+ breast cancer treatment methods | |
| JP6633170B2 (ja) | 移植患者における移植片対宿主病の治療 | |
| JP2017505761A5 (Direct) | ||
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2012131811A5 (Direct) | ||
| JP2017533972A5 (Direct) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| RU2020120156A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| JP2021130679A (ja) | 造血幹細胞移植患者の処置 | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
| MX2025009650A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico en el tratamiento de la esclerosis multiple | |
| NZ789516B2 (en) | AR+ breast cancer treatment methods | |
| WO2013018017A1 (en) | Antitumour combination comprising ombrabulin and cisplatin, associated with radiotherapy |